• Go HOME
  • Drug
    Development
  • Notice: Undefined offset: 2 in /home/host/nexelcatalog20/www/html/_skin/layout/inc_navigation_middle.php on line 60 Notice: Undefined offset: 2 in /home/host/nexelcatalog20/www/html/_skin/layout/inc_navigation_middle.php on line 86 Notice: Undefined offset: 3 in /home/host/nexelcatalog20/www/html/_skin/layout/inc_navigation_middle.php on line 86

Drug
DevelopmentFirst-in-class recombinant protein drug with anti-fibrotic effect

Nexel’s Pipelines Concept

NEXEL Pipelines

<Developing status, Sep 2020>

NP-011: Liver Disease (Liver Fibrosis)

  • Healthy Liver
  • Fibrosis Liver
Comparing therapeutic potential in liver fibrosis mouse model
  • Discovery from the secretome of stem cell-derived human hepatocytes (Gastroenterology, 2012&2017)
  • Identification of MFG-E8 responsible for the efficacy
  • Multiple variants designed from MFG-E8.
  • NP-011 became the lead candidate with significantly improved efficacy.

NP-011: STEMI (ST elevation myocardial infraction)

  • Heart Attack
  • NP-011 Treated : Protective Effect
Screening of efficacious dose in MI animal model
  • Reducing infarct region after NP-011 administration
  • Recovering 20% of EF & FS by NP-011 (follow up for 12 weeks)
  • Protecting cardiac cell death by mediating macrophages
  • NP-011 is very impressive because the molecule has recovered 20% rate of EF & FS in the disease animal model.

NP-011: STEMI (ST elevation myocardial infraction)

  • Excellent efficacy of NPT-002 in pulmonary fibrosis models
  • NPT-002 inhibits the transition of fibroblast to myofibroblast, the cause of IPF
  • Advantage of peptide is making it easy to manufacture medicines by synthesis of amino acids